reMYND drives the development of disease-modifying treatments against protein misfolding disorders.

Biotechnology

reMYND

Gerard Griffioen

Marc Fivaz

Steven Ramael

David Devigne

Ajit Shetty

Paul Van Dun

Jeffrey Cummings

Rudy Dekeyser

Kaj Blennow

Henrik Zetterberg

Goedele Ertveldt

Filip Goossens

This department is responsible for setting strategic direction and overseeing the organization's overall operations.

Executive Leadership

This department oversees the strategic direction and governance of the organization.

Board Leadership

The Clinical Advisory Team at reMYND provides expert guidance on clinical trial design, implementation, and interpretation to advance the development of treatments for protein misfolding disorders. Their insights help ensure that the clinical strategies are scientifically sound and aligned with regulatory standards, thereby optimizing patient outcomes and accelerating the path to market.

Clinical Advisory Team

This department is focused on the research and development of new pharmaceuticals through the discovery and evaluation of potential drug candidates.

Drug Discovery

This department oversees the implementation and management of quality, health, safety, and environmental standards in the organization.

Quality and Health Services

This department oversees financial management and operational processes to ensure efficiency and strategic alignment.

reMYND

Org chart

Board & advisors

Teams

Executive Leadership

Board Leadership

Clinical Advisory Team

Drug Discovery

Quality and Health Services

Finance and Operations

Offices

reMYND

Org chart

Board & advisors

Teams

Executive Leadership

Board Leadership

Clinical Advisory Team

Drug Discovery

Quality and Health Services

Finance and Operations

Offices

Related companies